Detailed narrative
Unity Confirm Launch and Strategic Impact
BillionToOne launched Unity Confirm, the first noninvasive fetal cell-based confirmation assay for high-risk NIPTs, at the ACOG Annual Meeting on May 1, 2026. This product captures and sequences intact circulating fetal cells from maternal blood, providing 100% fetal fraction, and aims to address the clinical gap for patients unwilling or unable to undergo invasive diagnostic testing. Initial results show 100% concordance with invasive diagnostics, and a large prospective study is enrolling patients. The company expects minimal direct revenue from Unity Confirm, but anticipates it will significantly differentiate its Unity Aneuploidy offering, as it is only accessible if Unity Aneuploidy is used as a frontline screen, driving increased volume for the core product.
Payer Contract Expansion and ASP Growth
The company significantly strengthened its market access by becoming in-network with Anthem, bringing total contracted lives to approximately 300 million in the U.S., representing over 90% of patients. This follows a similar agreement with UnitedHealthcare, effective April 1, 2026. These in-network contracts are expected to remove friction for physicians and patients, increase access, and lead to higher, more predictable average selling prices (ASPs) over time⏳, contributing to the raised full-year revenue guidance.
Oncology Business Growth and Future Outlook
Oncology revenue grew nearly 5x year-over-year to $10.7 million in Q1, driven by adoption of Northstar Select and Response, and recent launches of PGx and CH. Approximately 60% of Northstar Select orders now opt-in to CH. The company continues to see substantial opportunity in oncology, planning to expand its sales team, build clinical evidence, and pursue Medicare coverage for Northstar Response, which is expected to significantly increase its ASP and contribute to overall margin expansion once secured.
Operational Efficiency and Profitability Achievements
BillionToOne achieved GAAP profitability and positive cash flow with less than 10% of the accumulated deficit of public competitors, demonstrating strong fiscal discipline and efficient operations. The company delivered a 16% GAAP operating margin and 24% adjusted EBITDA margin in Q1, while continuing to invest meaningfully in its sales force, new product launches, and clinical evidence generation. This combination of rapid growth and profitability highlights the uniqueness of its technology and operational discipline.
Tumor-Naive MRD Test Development
The company is developing a tumor-naive MRD test, which is on track for launch by the end of 2026. Management believes this approach will be more easily adopted by community oncologists, who care for the majority of oncology patients in the U.S., expanding MRD usage beyond academic centers and colorectal cancer. The test will be launched with supporting data, likely through a manuscript, rather than at a specific conference.